Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1996 1
2002 2
2003 1
2004 3
2005 9
2006 4
2007 5
2008 2
2009 7
2010 10
2011 12
2012 8
2013 17
2014 26
2015 27
2016 19
2017 25
2018 21
2019 22
2020 42
2021 33
2022 32
2023 42
2024 17

Text availability

Article attribute

Article type

Publication date

Search Results

345 results

Results by year

Filters applied: . Clear all
Page 1
Proportion of inflammatory bowel diseases patients with suboptimal disease control in daily clinical practice-Real-world evidence from the inflammatory bowel diseases-podcast study.
D'Amico F, Gomollón F, Bamias G, Magro F, Targownik L, Leitner C, Heatta-Speicher T, Michelena N, Kolterer S, Lapthorn J, Kauffman L, Dignass A; IBD PODCAST investigators. D'Amico F, et al. Among authors: magro f. United European Gastroenterol J. 2024 May 11. doi: 10.1002/ueg2.12572. Online ahead of print. United European Gastroenterol J. 2024. PMID: 38733307 Free article.
Microbiota therapeutics for inflammatory bowel disease: the way forward.
Bethlehem L, Estevinho MM, Grinspan A, Magro F, Faith JJ, Colombel JF. Bethlehem L, et al. Among authors: magro f. Lancet Gastroenterol Hepatol. 2024 May;9(5):476-486. doi: 10.1016/S2468-1253(23)00441-7. Lancet Gastroenterol Hepatol. 2024. PMID: 38604201 Review.
Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensus.
Olivera PA, Dignass A, Dubinsky MC, Peretto G, Kotze PG, Dotan I, Kobayashi T, Ghosh S, Magro F, Faria-Neto JR, Siegmund B, Danese S, Peyrin-Biroulet L. Olivera PA, et al. Among authors: magro f. Dig Liver Dis. 2024 Apr 6:S1590-8658(24)00312-8. doi: 10.1016/j.dld.2024.03.010. Online ahead of print. Dig Liver Dis. 2024. PMID: 38584033 Free article. Review.
Accuracy of Information given by ChatGPT for patients with Inflammatory Bowel Disease in relation to ECCO Guidelines.
Sciberras M, Farrugia Y, Gordon H, Furfaro F, Allocca M, Torres J, Arebi N, Fiorino G, Iacucci M, Verstockt B, Magro F, Katsanos K, Busuttil J, De Giovanni K, Fenech VA, Chetcuti Zammit S, Ellul P. Sciberras M, et al. Among authors: magro f. J Crohns Colitis. 2024 Mar 23:jjae040. doi: 10.1093/ecco-jcc/jjae040. Online ahead of print. J Crohns Colitis. 2024. PMID: 38520394
Histologic assessments in ulcerative colitis: the evidence behind a new endpoint in clinical trials.
Pai RK, D'Haens G, Kobayashi T, Sands BE, Travis S, Jairath V, De Hertogh G, Park B, McGinnis K, Redondo I, Lipitz NG, Gibble TH, Magro F. Pai RK, et al. Among authors: magro f. Expert Rev Gastroenterol Hepatol. 2024 Jan-Feb;18(1-3):73-87. doi: 10.1080/17474124.2024.2326838. Epub 2024 Mar 21. Expert Rev Gastroenterol Hepatol. 2024. PMID: 38509826 Review.
Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study.
Allocca M, Catalano G, Savarino EV, Chaparro M, Levartovsky A, Michalopoulos G, Viazis N, Fousekis FS, Psistakis A, Noviello D, Nascimento CND, Caron B, Kitsou V, Bamias G, García MJ, Zacharopoulou E, Foteinogiannopoulou K, D'Amico F, Koutroubakis I, Ellul P, Tzouvala M, Peyrin-Biroulet L, Torres J, Caprioli F, Karmiris K, Theodoropoulou A, Katsanos KH, Christodoulou DK, Mantzaris GJ, Kopylov U, Gisbert JP, Danese S, Magro F, Carla F, Fiorino G. Allocca M, et al. Among authors: magro f. United European Gastroenterol J. 2024 Feb 28. doi: 10.1002/ueg2.12492. Online ahead of print. United European Gastroenterol J. 2024. PMID: 38419274 Free article.
Pragmatic trial design to compare real-world effectiveness of different treatments for inflammatory bowel diseases: the PRACTICE-IBD European consensus.
Fantini MC, Fiorino G, Colli A, Laharie D, Armuzzi A, Caprioli FA, Gisbert JP, Kirchgesner J, Macaluso FS, Magro F, Ghosh S; PRACTICE-IBD study group. Fantini MC, et al. Among authors: magro f. J Crohns Colitis. 2024 Feb 17:jjae026. doi: 10.1093/ecco-jcc/jjae026. Online ahead of print. J Crohns Colitis. 2024. PMID: 38367197 Free article.
The influence of subclinical active inflammation on IFX pharmacokinetic modeling and disease progression assessment: findings from a prospective real-world study in inflammatory bowel disease patients.
Magro F, Fernandes S, Patita M, Arroja B, Lago P, Rosa I, de Sousa HT, Ministro P, Mocanu I, Vieira A, Castela J, Moleiro J, Roseira J, Cancela E, Sousa P, Portela F, Correia L, Moreira P, Dias S, Afonso J, Danese S, Peyrin-Biroulet L, Vucicevic KM, Santiago M. Magro F, et al. J Crohns Colitis. 2024 Jan 19:jjae014. doi: 10.1093/ecco-jcc/jjae014. Online ahead of print. J Crohns Colitis. 2024. PMID: 38243908
345 results